Last $2.45 USD
Change Today -0.08 / -3.16%
Volume 1.1M
As of 8:10 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

synta pharmaceuticals corp (SNTA) Snapshot

Open
$2.52
Previous Close
$2.53
Day High
$2.55
Day Low
$2.39
52 Week High
02/25/14 - $7.22
52 Week Low
01/22/15 - $2.37
Market Cap
266.8M
Average Volume 10 Days
942.3K
EPS TTM
$-1.02
Shares Outstanding
108.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNTA PHARMACEUTICALS CORP (SNTA)

synta pharmaceuticals corp (SNTA) Related Businessweek News

No Related Businessweek News Found

synta pharmaceuticals corp (SNTA) Details

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its lead drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; and in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer. The company’s product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; and Elesclomol, a mitochondria-targeting agent that is in Phase 2 clinical trial for ovarian cancer. Its product pipeline in preclinical development stage for inflammatory diseases includes CRACM ion channel inhibitors for rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergy, transplant rejection, and other autoimmune diseases and inflammatory conditions; and IL-12/23 inhibitors for inflammatory and autoimmune diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.

134 Employees
Last Reported Date: 03/11/14
Founded in 2000

synta pharmaceuticals corp (SNTA) Top Compensated Officers

Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $486.3K
Compensation as of Fiscal Year 2013.

synta pharmaceuticals corp (SNTA) Key Developments

Synta Announces Presentation of Results from an Investigator-Sponsored Phase 1 Trial of Ganetespib in HER2+ Metastatic Breast Cancer

Synta Pharmaceuticals Corp. announced presentation of preliminary results from an investigator-sponsored phase 1 trial, designed to evaluate ganetespib in combination with paclitaxel and trastuzumab in women with HER2+ metastatic breast cancer (MBC) refractory to other HER2 inhibitors. The results are being presented during a poster session at the 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas. The phase 1 trial, conducted by physicians at New York University Langone Medical Center and Memorial Sloan Kettering Cancer Center, enrolled six heavily pretreated patients who received prior to entering the trial a edian of 3.5 anti-HER2 treatments in the metastatic setting (range 3-4), including trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1). Of the five patients evaluable for efficacy, partial tumor response was observed in one patient who remains on study, and four patients achieved stable disease ranging in duration from 11 to 29 weeks. Median Progression Free Survival was 19.4 weeks and the observed Clinical Benefit Rate (proportion of patients achieving objective response or stable disease greater than 24 weeks) was 60%.

Synta Pharmaceuticals Corp. Announces Executive Changes

Synta Pharmaceuticals Corp. announced the appointment of Chen Schor as a Executive Vice President and Chief Operating Officer and Marc Schneebaum as Senior Vice President and Chief Financial Officer, both effective as of December 8, 2014. Mr. Schneebaum will be replacing Keith S. Ehrlich, who will be stepping down as the Company's Chief Financial Officer, effective as of December 8, 2014. The two appointments bring significant financial, business development and operational experience in the biopharmaceutical industry to Synta. Mr. Schor served as Vice President, Global Branded Products Business Development at Teva Pharmaceuticals and at leadership positions in several emerging private and public companies Mr. Schneebaum brings over 25 years of experience in the biotechnology and healthcare sector to Synta. Most recently, he has served as a consultant in the healthcare industry. From 2011 to 2013, Mr. Schneebaum served as President, Chief Executive Officer and a director of Predictive BioSciences Inc., a commercial stage cancer diagnostics company.

Synta Pharmaceuticals Corp. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 02:25 PM

Synta Pharmaceuticals Corp. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 02:25 PM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Vujo Vukovic, Senior Vice President and Chief Medical Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNTA:US $2.45 USD -0.08

SNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNTA.
View Industry Companies
 

Industry Analysis

SNTA

Industry Average

Valuation SNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNTA PHARMACEUTICALS CORP, please visit www.syntapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.